Copyright © 1994 by the European Society of Cardiology.
© 1994 The European Society of Cardiology
Serum ferritin and ceruloplasmin as coronary risk factors
*First Department of Medicine, University of Helsinki Finland
National Public Health Institute Helsinki
Department of Public Health, University of Helsinki Finland
Received 14 March 1993; revised 13 June 1994; .
Correspondence: Matti Mänttärri, MD, First Department of Medicine, Helsinki University Central Hospital, Haartmaninkatu 4, SF 00290 Helsinki, Finland.
Abstract
Iron and copper catalyze lipid peroxidation in vitro, and recent epidemiological data suggest that these metal ions might also be involved in human coronary heart disease. We tested the hypothesis by investigating whether the storage proteins ferritin and ceruloplasmin were coronary risk factors.
A nested case-control study was set up in middle-aged dyslipidaemic participants of the Helsinki Heart Study: a placebo-controlled coronary primary prevention trial with gemfibrozil Of the 140 subjects with cardiac end-points (non-fatal myocardial infarction or cardiac death) 136 were matched with controls for geographical area and drug treatment (gemfibrozil-placebo).
Frozen baseline serum samples were used in the analyses of ferritin and ceruloplasmin. Using logistic regression analyses no increment in coronary risk was detected with increasing ferritin levels (P=0.8 for trend). Ceruloplasmin was higher 349 ± 86 vs 317 ± 77mg. l–1 (P<0.001) in cases than in controls and the risk in the highest fertile was two-fold (odds ratio 21; 95% CI 1.3-4.2) compared to the lowest (P<0.005 for trend). The risk of high ceruloplasmin was influenced by lipoprotein cholesterol concentrations, with an odds ratio of 2.4 (95% CI 1.3-4.4) in subjects with high low density lipoprotein cholesterol and of 11.3 (95% CI 2.5-52.2) in subjects with low high density lipoprotein cholesterol.
It was concluded that ferritin was not associated with coronary heart disease in dyslipidaemic, middle-aged men, while there was a continuous and graded increment in coronary risk with elevating ceruloplasmin level.
Key Words: Coronary heart disease • ceruloplasmin • ferritin • cholesterol • HDL-cholesterol • gemfibrozil
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. G. Makedou, D. P. Mikhailidis, A. Makedou, S. Iliadis, A. Kourtis, N. Vavatsi-Christaki, and G. E. Papageorgiou Lipid Profile, Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families With a Positive History of Cardiovascular Diseases and/or Hyperlipidemia Angiology, August 1, 2009; 60(4): 455 - 461. [Abstract] [PDF]
|
|
|
|
 |
|
 Q. Sun, J. Ma, N. Rifai, O. H. Franco, K. M. Rexrode, and F. B. Hu Excessive Body Iron Stores Are Not Associated with Risk of Coronary Heart Disease in Women J. Nutr., December 1, 2008; 138(12): 2436 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Brewer Iron and Copper Toxicity in Diseases of Aging, Particularly Atherosclerosis and Alzheimer's Disease Experimental Biology and Medicine, February 1, 2007; 232(2): 323 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Aidinian, J. M. Weiswasser, S. Arora, C. J. Abularrage, N. Singh, and A. N. Sidawy Carotid Plaque Morphologic Characteristics Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2006; 18(1): 63 - 70. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E.R. Kartikasari, N. A. Georgiou, F. L.J. Visseren, H. van Kats-Renaud, B. S. van Asbeck, and J. J.M. Marx Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial Cells Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2257 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ramakrishna, T. W Rooke, and L. T Cooper Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light Vascular Medicine, August 1, 2003; 8(3): 203 - 210. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J Fleming, K. L Tucker, P. F Jacques, G. E Dallal, P. W. Wilson, and R. J Wood Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1375 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haidari, E. Javadi, A. Sanati, M. Hajilooi, and J. Ghanbili Association of Increased Ferritin with Premature Coronary Stenosis in Men Clin. Chem., September 1, 2001; 47(9): 1666 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J Fleming, P. F Jacques, J. M Massaro, R. B D'Agostino Sr, P. W. Wilson, and R. J Wood Aspirin intake and the use of serum ferritin as a measure of iron status Am. J. Clinical Nutrition, August 1, 2001; 74(2): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ascherio, E. B. Rimm, E. Giovannucci, W. C. Willett, and M. J. Stampfer Blood Donations and Risk of Coronary Heart Disease in Men Circulation, January 2, 2001; 103(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Chisolm III, S. L. Hazen, P. L. Fox, and M. K. Cathcart The Oxidation of Lipoproteins by Monocytes-Macrophages. BIOCHEMICAL AND BIOLOGICAL MECHANISMS J. Biol. Chem., September 10, 1999; 274(37): 25959 - 25962. [Full Text] [PDF]
|
|
|
|
 |
|
 B. de Valk and J. J. M. Marx Iron, Atherosclerosis, and Ischemic Heart Disease Arch Intern Med, July 26, 1999; 159(14): 1542 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bianchini, G. Musci, and L. Calabrese Inhibition of Endothelial Nitric-oxide Synthase by Ceruloplasmin J. Biol. Chem., July 16, 1999; 274(29): 20265 - 20270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Klipstein-Grobusch, J. F Koster, D. E Grobbee, J. Lindemans, H. Boeing, A. Hofman, and J. C. Witteman Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study Am. J. Clinical Nutrition, June 1, 1999; 69(6): 1231 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Danesh and P. Appleby Coronary Heart Disease and Iron Status : Meta-Analyses of Prospective Studies Circulation, February 23, 1999; 99(7): 852 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-P. Tuomainen, K. Punnonen, K. Nyyssonen, and J. T. Salonen Association Between Body Iron Stores and the Risk of Acute Myocardial Infarction in Men Circulation, April 21, 1998; 97(15): 1461 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cappelli-Bigazzi, G. Ambrosio, G. Musci, C. Battaglia, M. C. B. Di Patti, P. Golino, M. Ragni, M. Chiariello, and L. Calabrese Ceruloplasmin impairs endothelium-dependent relaxation of rabbit aorta Am J Physiol Heart Circ Physiol, December 1, 1997; 273(6): H2843 - H2849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Mukhopadhyay, B. Mazumder, P. F. Lindley, and P. L. Fox Identification of the prooxidant site of human ceruloplasmin: A model for oxidative damage by copper bound to protein surfaces PNAS, October 14, 1997; 94(21): 11546 - 11551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hemila, M. Paunio, T.-P. Tuomainen, R. Salonen, K. Nyyssonen, and J. T Salonen Blood donation, body iron stores, and risk of myocardial infarction BMJ, June 21, 1997; 314(7097): 1830 - 1830. [Full Text]
|
|
|
|
|
|
C. K. Mukhopadhyay, E. Ehrenwald, and P. L. Fox Ceruloplasmin Enhances Smooth Muscle Cell- and Endothelial Cell-mediated Low Density Lipoprotein Oxidation by a Superoxide-dependent Mechanism J. Biol. Chem., June 21, 1996; 271(25): 14773 - 14778. [Abstract] [Full Text] [PDF]
|
|